In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

Treatment-emergent adverse events (TEAEs) occurred in a similar proportion of patients in each group, and were mostly mild or ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...

Data from two more late-stage studies show that treatment with Amgen's rocatinlimab improves outcomes in atopic dermatitis indication.

Amgen (AMGN) and Kyowa Kirin (KYKOF) announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an ...

Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...

Sapiens International Corporation , a leading global provider of software solutions for the insurance industry, announced ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...